Efficacy and prognosis of neoadjuvant immunotherapy in combination with chemotherapy in non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200060433

Enrollment

Unknown

Registered

2022-06-01

Start date

2022-05-20

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Group 1:Neoadjuvant chemotherapy

Group 2:Neoadjuvant immunotherapy combined with chemotherapy

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20-80 years; 2. Newly diagnosed with non-small cell lung cancer; 3. The first MDT assessment was resectable lung cancer; 4. Receive neoadjuvant therapy (including neoadjuvant immunotherapy or neoadjuvant chemotherapy); 5. Surgical excision with definite postoperative pathological diagnosis.

Exclusion criteria

Exclusion criteria: 1. Poor cardiopulmonary function, unable to tolerate surgery; 2. After the second MDT evaluation, the lesion progressed to unresectable or distant metastasis after neoadjuvant therapy; 3. Refusal to follow up.

Design outcomes

Primary

Measure	Time frame
Survival time;	—

Secondary

Measure	Time frame
Major pathological response;	—

Countries

China

Contacts

Public ContactDai Fuqiang

Army Medical Center of PLA (Daping Hospital)

daifuqiangd@163.com+86 15123095770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026